Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Drinking roughly 2 liters of water in the 24 hours before an intravenous bisphosphonate infusion, such as zoledronic acid or pamidronate, keeps urine flowing and dilutes the drug so it clears through the kidneys instead of concentrating in the renal tubules, where it can trigger injury. Good hydration also supports steady blood flow to the kidneys, reduces the chance of a temporary rise in creatinine, and can soften common post-infusion effects like fever, aches, and fatigue. Fluid targets are not identical for everyone, because heart failure, existing kidney disease, diuretics, and other medications change how much you should safely drink, so there are several important factors to consider below. If you are noticing signs such as reduced urination, swelling, or unusual fatigue before or after an infusion, a free, instant, online symptom check can help you sort out what your body is signaling and how quickly you should act. It takes only a few minutes, costs nothing, and gives you clearer language and better questions to bring to your care team.
Last reviewed for medical accuracy: 08/18/2026
When you’re scheduled for a bisphosphonate infusion such as Reclast (zoledronic acid), proper hydration is a simple yet powerful way to support kidney health. Bisphosphonates are medications that help strengthen bones and reduce fracture risk, but they rely on efficient kidney filtration for safe elimination. Following a well-established Reclast zoledronic acid hydration protocol—namely drinking about 2 liters of water before your infusion—can lower the chance of kidney stress or injury.
Optimizes Kidney Perfusion
Dilutes Urinary Solutes
Maintains Electrolyte Balance
Clinical guidelines and product literature for zoledronic acid consistently recommend ensuring good hydration before and after each infusion. A practical hydration protocol may include:
Reaching 2 liters doesn’t have to feel like a chore. Try these simple strategies:
In addition to hydration, consider these steps to keep your kidneys safe during your zoledronic acid infusion:
Most people tolerate zoledronic acid well when properly hydrated, but it’s wise to know what to watch for:
If any of these symptoms arise, speak to your healthcare provider right away. For non-urgent concerns, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get guidance on next steps.
Bisphosphonates like Reclast offer significant advantages for bone health—lowering the chance of painful fractures and improving mobility. However, any powerful medication comes with potential risks. By following a simple hydration protocol, you tilt the balance strongly toward benefit:
Always discuss any major medical decisions with your healthcare team. If you experience:
speak to a doctor immediately. Your provider can tailor the Reclast zoledronic acid hydration protocol to your unique health needs and address any serious concerns.
Drinking 2 liters of water before a zoledronic acid infusion is a straightforward, proven approach to safeguard your kidneys and maximize the benefits of bisphosphonate therapy. By combining proper hydration with routine lab monitoring and healthy lifestyle habits, you can confidently move forward with your treatment plan. For a personalized health check, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. And remember—always speak to a doctor about anything that could be life threatening or serious.
(References)
* Ziegler R. [Hypercalcemia]. Ther Umsch. 2000 Jun;57(6):391-7. doi: 10.1024/0040-5930.57.6.391. PMID: 10894025.
* Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol. 2001 Aug;2(4):347-54. doi: 10.1007/s11864-001-0028-2. PMID: 12057115.
* Udelsman R. Primary hyperparathyroidism. Curr Treat Options Oncol. 2001 Aug;2(4):365-72. doi: 10.1007/s11864-001-0030-8. PMID: 12057117.
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Steinberg SJ, Raymond GV, Braverman NE, Moser AB. Zellweger Spectrum Disorder. 1993. PMID: 20301621.
* Feldenzer KL, Sarno J. Hypercalcemia of Malignancy. J Adv Pract Oncol. 2018 Jul-Aug;9(5):496-504. 2018 Jul 1. PMID: 31086686; PMCID: PMC6505545.
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Akesson LS, Savarirayan R. Fibrodysplasia Ossificans Progressiva. 1993. PMID: 32525643.
* Hu MI. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021 Dec;50(4):721-728. doi: 10.1016/j.ecl.2021.07.003. PMID: 34774243.
* Tonon CR, Silva TAAL, Pereira FWL, Queiroz DAR, Junior ELF, Martins D, Azevedo PS, Okoshi MP, Zornoff LAM, de Paiva SAR, Minicucci MF, Polegato BF. A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia. Med Sci Monit. 2022 Feb 26;28:e935821. doi: 10.12659/MSM.935821. 2022 Feb 26. PMID: 35217631; PMCID: PMC8889795.
* Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022 Oct 25;328(16):1624-1636. doi: 10.1001/jama.2022.18331. PMID: 36282253.
* Almuradova E, Cicin I. Cancer-related hypercalcemia and potential treatments. Front Endocrinol (Lausanne). 2023;14:1039490. doi: 10.3389/fendo.2023.1039490. 2023 Mar 22. PMID: 37033238; PMCID: PMC10073684.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.